TRASIS has successfully acquired its distributor and established a joint venture with Beijing PET Technology in China, marking a key strategic move to enhance its presence in the rapidly growing nuclear medicine market.
Target Information
TRASIS is a leading global provider of equipment and consumables utilized in the diagnostic and treatment of tumors via nuclear medicine. The company prides itself on its innovative solutions that make radiopharmaceutical tracers accessible to the global medical community. Recently, TRASIS undertook a strategic move aimed at enhancing its international development by acquiring its distributor and establishing a joint venture in China.
This acquisition marks a significant milestone in TRASIS's growth strategy, highlighting its commitment to deepening its presence in key markets. The joint venture, established with Beijing PET Technology, illustrates TRASIS's ambition to transform its distribution relationship into a sustainable structural presence in China.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview
The nuclear medicine industry plays a vital role in the healthcare sector, particularly in cancer diagnosis and treatment. In China, the demand for advanced medical technologies has been on the rise, spurred
Similar Deals
VivaVision → Jiangxi Shanliang Pharmaceutical Co., Ltd.
2024
TRASIS
invested in
Beijing PET Technology
in 2025
in a Joint Venture deal